Suboxone $385 Million Settlement Receives Final Court Approval, Faruqi & Faruqi, LLP, Co-Lead Counsel

On February 27, 2024, Judge Mitchell S. Goldberg of the United States District Court for the Eastern District of Pennsylvania granted final approval to a $385 million settlement in In re Suboxone Antitrust Litigation, 13-md-02445 (E.D. Pa.).  The settlement represents one of the largest of its kind for a direct purchaser class action involving allegations of monopolization and an anticompetitive market switch in the pharmaceutical industry.  Suboxone is an opioid addiction treatment that the plaintiffs alleged was improperly switched from a tablet to film version in order to maintain monopoly profits.  Faruqi & Faruqi served as co-lead counsel for the class.  The court remarked that class counsel were “skilled and effective class action litigators” that engaged in “intensive advocacy and negotiation.”  The court additionally noted that the response to the settlement from class members was “overwhelmingly favorable” and that no class member objected.    
 
The opinion can be read here.